Principal Securities »

Innate Pharma shares owned by Principal Securities

Quarter-by-quarter ownership of Innate Pharma (IPHA) shares owned by Principal Securities from 13F filings

Historical chart of Principal Securities investment in Innate Pharma

Tip: Access up to 7 years of quarterly data

All positions including Innate Pharma held by Principal Securities consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Innate Pharma by Principal Securities

Quarter filed Position value Share count Share price at filing
2025-09-30 $86 45 1.93
2025-06-30 $81 45 1.82

More positions owned by Principal Securities

Principal Exchange Traded Us Mega Cp Etf (USMC)
Ishares Tr Core S&p500 Etf (IVV)
Ishares Tr Core Us Aggbd Et (AGG)
Principal Exchange Traded Focused Blue Chi (BCHP)
Principal Exchange Traded Prin U S Small (PSC)
Goldman Sachs Etf Tr Marketbeta Us Eq (GSUS)
Microsoft Corporation (MSFT)
Principal Exchange Traded Intl Equity Etf (PIEQ)
Ishares Tr Core S&p Us Vlu (IUSV)
Spdr Series Trust Portfolio S&p500 (SPLG)
NVIDIA Corporation (NVDA)
Amazon (AMZN)
Apple (AAPL)
Principal Exchange Traded Prnc Invt Grad (IG)
Ishares Tr Rus 1000 Etf (IWB)

View all positions for Principal Securities

Top funds holding Innate Pharma

Morgan Stanley
Citadel Advisors
UBS Group
GAMMA Investing
Rhumbline Advisers
Barclays
Optiver Holding B.V.
Principal Securities
Farther Finance Advisors

View all funds holding Innate Pharma